Table 1 Characteristics of included studies

From: Efficacy of PDE-5-inhibitors for erectile dysfunction. A comparative meta-analysis of fixed-dose regimen randomized controlled trials administering the International Index of Erectile Function in broad-spectrum populations

First author, year of publication Ref. Drug, dose (mg) Treatment duration (weeks) Study population Mean age (years) ED etiology organic/psychogenic EF baseline score Jadad-score
Montorsi, 1999 23 Sildenafil, 100 12 514 men 56 32%/25% 12.6 3
Shirai, 2000 25 Sildenafil, 100 8 256 Japanese men 53 18%/29% 10.0 NE
Padma-Nathan, 2003 24 Sildenafil, 100 4 228 men 63 64%/3% 13.3 3
Padma-Nathan, 2001 30 Tadalafil, 25 3 179 men 56 NE 15.0 3
Faria, 2003 29 Tadalafil, 20 12 204 Brazilian men 54 31%/22% 16.1 NE
(Approval study LVCO), 2004 31 Tadalafil, 20 12 197 Taiwanese men 60 NE 15.6 3
(Approval study LVCQ), 2004 31 Tadalafil, 20 12 140 Australian men 59 42%/8% 15.6 3
(Approval study LVDJ), 2004 31 Tadalafil, 20 12 253 Canadian men 59 59%/NE 15.0 3
(Approval study USA A), 2004a 31 Tadalafil, 20 12 402 American men 59 NE 13.1 NE
(Approval study USA B), 2004a 31        
Brock, 2001 28 Tadalafil, 25 8 212 men 58 NE 15.1 NE
Porst, 2001 12 Vardenafil, 20 12 601 men 52 32%/26% 14.0 3
Hellstrom, 2002 11 Vardenafil, 20 26 805 men 57 57%/7% 12.9 4
[Approval study 10128], 2003 33 Vardenafil, 20 12 845 men 55 NE 13.1 3
  1. Ref.: reference; NE: not eligible.
  2. aCharacteristics available only pooled for both studies.